Neupogen - (0.6 mg/ml; Injection)

Generic Name	Filgrastim	Innovator	Amgen
Dosage	0.6 mg/ml; Injection	Branded US Sales	Less Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	Less Than 5
Indication	NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******			*******	******** ** ******	******** ** **** *, ****
******			******* \ *** ** ** ** '*** ******	****	****** **** ********
****** ******			*******	******** ** *******	******** ** *** ****

Chronology Of Events